Lisata Therapeutics Enters Material Definitive Agreement
Ticker: LSTA · Form: 8-K · Filed: Dec 3, 2024 · CIK: 320017
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action, pharmaceuticals
Related Tickers: CLBS
TL;DR
Lisata Therapeutics just signed a big deal, filing a material definitive agreement on Dec 3rd.
AI Summary
On December 3, 2024, Lisata Therapeutics, Inc. (formerly Caladrius Biosciences, Inc.) entered into a Material Definitive Agreement. The company, incorporated in Delaware, is involved in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates a significant new contract or partnership for Lisata Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry significant risks related to the terms, obligations, and potential outcomes of the agreement.
Key Numbers
- 001-33650 — SEC File Number (Identifies the company's filing history with the SEC.)
- 22-2343568 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- LISATA THERAPEUTICS, INC. (company) — Registrant
- CALADRIUS BIOSCIENCES, INC. (company) — Former company name
- December 3, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 110 Allen Road, Second Floor, Basking Ridge, NJ 07920 (address) — Principal Executive Offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Lisata Therapeutics?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on December 3, 2024.
When was Lisata Therapeutics, Inc. previously known as?
Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc., and prior to that, NeoStem, Inc.
Where are Lisata Therapeutics' principal executive offices located?
Lisata Therapeutics' principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
What is the Standard Industrial Classification code for Lisata Therapeutics?
The Standard Industrial Classification code for Lisata Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Lisata Therapeutics?
The fiscal year end for Lisata Therapeutics is December 31.
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 14.8 · Accepted 2024-12-03 08:33:26
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LSTA The Nasdaq Capital Marke
- $1.0 million — (i) pay an upfront cash license fee of $1.0 million within twelve (12) months of the date o
- $1.5 million — development milestone payments of up to $1.5 million upon the achievement of specified regul
- $17.5 million — commercial milestone payments of up to $17.5 million upon the achievement of specified comme
Filing Documents
- clbs-20241203.htm (8-K) — 24KB
- 0000320017-24-000061.txt ( ) — 149KB
- clbs-20241203.xsd (EX-101.SCH) — 2KB
- clbs-20241203_lab.xml (EX-101.LAB) — 22KB
- clbs-20241203_pre.xml (EX-101.PRE) — 13KB
- clbs-20241203_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Exclusive License and Collaboration Agreement On November 30, 2024, Lisata Therapeutics, Inc. (the "Company") entered into an exclusive license and collaboration agreement (the "License and Collaboration Agreement" or the "Agreement") with Kuva Labs, Inc. a wholly-owned subsidiary of Mi2 Holdings, LLC ("Kuva"), pursuant to which the Company granted a worldwide royalty bearing exclusive license (the "Exclusive License") for the development and commercialization of certepetide (the "Licensed Products") and a worldwide non-exclusive license (the "Non-Exclusive License", and together with the Exclusive License, the "Licenses") to develop and commercialize the Licensed Products using the know-how of the Sanford Burnham Prebys Medical Discovery Institute ("SBP", and such know-how the "Licensed SBP Patents") previously granted to the Company pursuant to a license agreement by and between the Company and SBP (the "SBP License Agreement"). Under the Agreement, Kuva will assume full responsibility for research, development, and commercialization costs, while the Company will be responsible for supplying certepetide pursuant to a Clinical Supply Agreement for clinical use and pursuant to a Commercial Supply Agreement to be entered into by the parties after regulatory approval of a Licensed Product. The strategic partnership between the Company and Kuva is expected to explore the synergistic potential of Lisata's novel iRGD cyclic peptide certepetide as a targeting and delivery agent for Kuva's NanoMark imaging technology in solid tumors. In consideration of the rights and Licenses under the License and Collaboration Agreement, Kuva agreed to, in the aggregate, (i) pay an upfront cash license fee of $1.0 million within twelve (12) months of the date of the Agreement, payable in four (4) installments as set forth in the Agreement, (ii) pay development milestone payments of up to $1.5 million upon the achievement of specifi
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LISATA THERAPEUTICS, INC. By: /s/ David J. Mazzo Name: David J. Mazzo, PhD Title: President and Chief Executive Officer Dated: December 3, 2024